General Information of Drug (ID: DMP7J0S)

Drug Name
R411 Drug Info
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Cross-matching ID
PubChem CID
61516
CAS Number
CAS 10415-87-9
TTD Drug ID
DMP7J0S

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AJM-300 DM5K6J4 Crohn disease DD70 Phase 3 [2]
TRK-170 DM13G5R Inflammatory bowel disease DD72 Phase 2 [3]
CDP323 DMXYLTI Multiple sclerosis 8A40 Phase 2 [4]
Firategrast DMW2QYT Multiple sclerosis 8A40 Phase 2 [5]
HMR-1031 DM695QT Arthritis FA20 Phase 1 [6]
BIIB107 DMIA57S Multiple sclerosis 8A40 Phase 1 [7]
TR-14035 DMWD39E Multiple sclerosis 8A40 Discontinued in Phase 1 [8]
CY-9652 DMPBCLA Inflammation 1A00-CA43.1 Terminated [9]
TCS2314 DMBVYQR Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-4/beta-1 (ITGA4/B1) TT6S84X ITA4_HUMAN-ITB1_HUMAN Modulator [1]

References

1 Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010 Oct;9(10):804-20.
2 Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013 Dec;7(11):e533-42.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.PLoS One.2013;8(3):e58438.
5 Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.Lancet Neurol.2012 Feb;11(2):131-9.
6 Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler. Am J Ther. 2004 Mar-Apr;11(2):103-13.
7 ClinicalTrials.gov (NCT04593121) A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB107 in Healthy Adult Participants. U.S.National Institutes of Health.
8 Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. Xenobiotica. 2005 Apr;35(4):373-89.
9 US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2580).